THE QUESTIONNAIRE SURVEY ON THE USE OF NEBULIZER THERAPY FOR CHRONIC PARANASAL SINUSITIS

• Published in: JIBI INKOKA TEMBO Vol. 41; no. Supplement1; pp. 31 - 36
• Main Authors: Komiya, Takashi, Koyama, Satoru, Ishizuka, Youichi
• Format: Journal Article
• Language: Japanese
• Published: Society of Oto-rhino-laryngology Tokyo 1998
• Subjects: chronic inflammation of paranasal sinuses; nebulizer therapy; questionnaire survey
• ISSN: 0386-9687; 1883-6429
• DOI: 10.11453/orltokyo1958.41.Supplement1_31

The use of CMX in nebulizer therapy was permitted in September 1996, and hence we have recently conducted a questionnaire survey on the current situation regarding the use status of antimicrobial agents, criteria for selection and use conditions of nebulizer (time required for a single treatment, starting age, duration of the therapy, other drugs used together, any examination/treatment provided before starting the therapy, and instruments employed). The subjects for the survey were 199 otorhinolaryngologists in Japan including mainly those working or practicing in areas surrounding Mizonokuchi Hospital of Teikyo University. The respondents were 142 in total (including 88 medical practitioners, 32 working for hospitals, and 12 working for clinics), for a reply rate of 71.4%. For use conditions of nebulizer, the results obtained were almost the same as those obtained 8 years ago. As a result of approval, CMX has emerged as No. 1 of the antibiotics used. The survery also revealed that such drugs as fosfomycin, new quinolones, etc. which were not previously available are in use.